LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
-2.99%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$260M
AUM Growth
+$260M
(-26%)
Cap. Flow
-$39.8M
Cap. Flow
% of AUM
-15.27%
Top 10 Holdings %
Top 10 Hldgs %
50.97%
Holding
59
New
21
Increased
10
Reduced
8
Closed
19
Top Buys
| 1 |
AbbVie
ABBV
|
$20.2M |
| 2 |
Moderna
MRNA
|
$13.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
$10.8M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$9.5M |
| 5 |
Passage Bio
PASG
|
$8.96M |
Top Sells
| 1 |
AMRN
Amarin Corp
AMRN
|
$20.6M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$18M |
| 3 |
BLUE
bluebird bio
BLUE
|
$17.9M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$15.9M |
| 5 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$14.2M |
Sector Composition
| 1 | Healthcare | 93.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$372B
| $20.2M | 7.7% | +265,600 | New | +$20.2M |
|
2
Sarepta Therapeutics
SRPT
$1.78B
| $18.3M | 6.97% | 187,350 -38,652 | -17% | -$3.78M |
|
|
MYOK
3
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $14.1M | 5.35% | 300,000 +68,991 | +30% | +$3.23M |
|
|
4
Moderna
MRNA
$9.37B
| $13.8M | 5.24% | +460,000 | New | +$13.8M |
|
5
Ascendis Pharma
ASND
$11.8B
| $13.5M | 5.14% | 120,000 -59,898 | -33% | -$6.75M |
|
|
RETA
6
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $11.9M | 4.52% | 82,292 +26,592 | +48% | +$3.84M |
|
|
7
Bristol-Myers Squibb
BMY
$96B
| $10.8M | 4.12% | +194,500 | New | +$10.8M |
|
8
Zymeworks
ZYME
$1.12B
| $10.8M | 4.11% | 304,417 -84,736 | -22% | -$3.01M |
|
|
IGMS
9
DELISTED
IGM Biosciences
IGMS
| $9.76M | 3.71% | 173,865 +59,454 | +52% | +$3.34M |
|
|
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $9.5M | 3.61% | +185,933 | New | +$9.5M |
|
|
11
Passage Bio
PASG
$22.7M
| $8.96M | 3.41% | +603,338 | New | +$8.96M |
|
12
Vertex Pharmaceuticals
VRTX
$100B
| $7.91M | 3.01% | +33,237 | New | +$7.91M |
|
|
BLU
13
DELISTED
BELLUS Health Inc.
BLU
| $7.74M | 2.94% | 775,377 +350,759 | +83% | +$3.5M |
|
14
Iovance Biotherapeutics
IOVA
$807M
| $7.4M | 2.82% | 247,248 +26,705 | +12% | +$799K |
|
15
Fulcrum Therapeutics
FULC
$351M
| $6.36M | 2.42% | 532,520 +408,885 | +331% | +$4.88M |
|
16
89bio
ETNB
$1.34B
| $6.24M | 2.37% | 247,000 +160,409 | +185% | +$4.05M |
|
|
MTEM
17
DELISTED
Molecular Templates, Inc.
MTEM
| $5.83M | 2.22% | 438,831 +98,931 | +29% | +$1.31M |
|
18
Verastem
VSTM
$569M
| $5.53M | 2.1% | +2,325,582 | New | +$5.53M |
|
|
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $5.02M | 1.91% | 69,658 +30,011 | +76% | +$2.16M |
|
|
BMY.RT
20
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $4.85M | 1.84% | 1,275,500 -2,047,316 | -62% | -$7.78M |
|
21
10x Genomics
TXG
$1.74B
| $4.54M | 1.73% | +72,831 | New | +$4.54M |
|
22
CRISPR Therapeutics
CRSP
$4.71B
| $4.48M | 1.7% | +105,512 | New | +$4.48M |
|
|
BPMC
23
DELISTED
Blueprint Medicines
BPMC
| $4.39M | 1.67% | +75,000 | New | +$4.39M |
|
24
Alnylam Pharmaceuticals
ALNY
$58.5B
| $4.32M | 1.64% | +39,644 | New | +$4.32M |
|
25
Fate Therapeutics
FATE
$120M
| $4.29M | 1.63% | +193,144 | New | +$4.29M |
|